-
05/11/2024
"In silico trials: an updated SWOT Analysis" released by In Silico World
The document comprehensively examines the strengths, weaknesses, opportunities, and threats for In Silico Trials in healthcare, providing a roadmap to help biomedical companies navigate and adopt these innovative methodologies.
-Read more-
-
31/10/2024
In the literature: October 2024 highlights
Click here to read some interesting recently published papers from our community. If you have published an article in the field of in silico medicine, send it to us: we will include it in this section of the newsletter!
-Read more-
-
31/10/2024
Joint motion for a resolution to revise the Medical Devices Regulation
The European Parliament has voted with a large majority to urge the European Commission to implement critical amendments to the EU Medical Device Regulation (MDR) by the first quarter of 2025. The drive for reform is intended to tackle pressing issues in the regulation, which has been criticised for its excessive bureaucracy and impact on patient care, jobs, and innovation in the medical device sector.
-Read more-
-
31/10/2024
EU Budget for 2025 Prioritizes Research, Health, Education, and Climate Action
The European Parliament has presented their draft budget demanding an EU budget for 2025 that focuses on improving
people's lives, boosting competitiveness, and addressing current challenges. MEPs are proposing a budget of nearly
€201 billion, which exceeds the European Commission's initial proposal of around €199.76 billion.
-Read more-
-
31/10/2024
EMA publishes a reflection paper on AI in medicinal product lifecycle
The European Medicines Agency has recently published a reflection paper on the integration of artificial intelligence (AI)
throughout the lifecycle of medicinal products.
-Read more-
-
31/10/2024
Network strategy to 2028: public consultation
The draft European Medicines Agencies Network Strategy to 2028 is available for public consultation. The deadline to comment is 30 November 2024.
-Read more-
-
30/10/2024
Speeding up Duchenne Muscular Dystrophy therapies with a model-based clinical trial simulator
Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder causing muscle deterioration. Despite advances, no cure exists, and current treatments only slow progression. To support drug development, the FDA’s Critical Path Initiative and C-Path’s Duchenne Regulatory Science Consortium (D-RSC) launched a clinical trial simulation tool. This tool optimizes trials, supporting regulatory approval and speeding new therapies to market.
-Read more-
-
22/10/2024
PhD and postdoc opportunities - October 2024
New calls with deadlines end October - early November
-Read more-
